Pacific Edge Limited AI Stock Analysis
Want to see NZ:PEB full AI Analyst Report?
Pacific Edge Limited (PEB) AI Stock Analysis
Pacific Edge Limited
(NZX:PEB)
The score is primarily held down by very weak financial performance—sharp FY2026 revenue contraction, negative gross profit, and ongoing cash burn alongside significant equity erosion. Technicals are also soft with weak momentum and the price below key short- to mid-term moving averages, offering only limited signs of stabilization. Valuation is constrained by losses (negative P/E) and no indicated dividend support.
Pacific Edge Limited (PEB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- NZD 167.59M
- Dividend Yield
- ―
- Average Volume (3M)
- 757.48K
- Price to Earnings (P/E)
- -6.7
- Beta (1Y)
- -1.19
- Revenue Growth
- -47.36%
- EPS Growth
- -3.79%
- Country
- NZ
- Employees
- 114
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Pacific Edge Limited Business Overview & Revenue Model
Company Description
Based in Dunedin, New Zealand, Pacific Edge Limited, established in 2001, operates as a cancer diagnostics firm. The company's core mission involves the research, development, and commercialization of advanced diagnostic and prognostic tools aimed at...
Pacific Edge Limited Earnings Call Summary
The earnings call presents a mixed view, with notable strategic achievements and promising future prospects, particularly with the upcoming Contractor Advisory Committee. However, significant challenges remain due to reduced revenue, test volumes, and the impact of Medicare non-coverage, creating financial strains and operational hurdles.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
In the Pacific Edge 1H Financial Results Presentation for Fiscal Year 2026, the company reported a net loss of $19.1 million and operating revenue of $5.9 million, down from $10.9 million in the previous period. Cash reserves were at $22.1 million, partly bolstered by a $20.7 million capital raise in August 2025. The company faced challenges due to a Medicare non-coverage determination, impacting test volumes and revenue, especially in the U.S. However, Pacific Edge achieved a milestone with Triage Plus, securing a price of USD 1,328 per test, up from $760. Sales force efficiency was maintained, with a sales FTE average of 12, down from over 30, reflecting cost management efforts. The company is optimistic about a potential Medicare re-coverage following a Contractor Advisory Committee (CAC) meeting scheduled for February 19, 2026. They are appealing over 2,000 denied tests to Medicare and commercial providers, expecting revenue recognition in the second half of the year. Additionally, Pacific Edge is pursuing international market expansion with IVD products and focusing on product innovation like Triage Plus and Surveillance Plus for long-term growth.
Pacific Edge Limited Financial Statement Overview
Summary
Overall fundamentals are very weak: sustained operating losses and deeply negative net margins, with FY2026 revenue down ~32% YoY and gross profit turning negative. Cash flow remains materially negative (FY2026 operating cash flow about -31.9M; free cash flow about -32.1M), indicating ongoing cash burn. A partial offset is low leverage, but equity has eroded sharply (about 116.6M in FY2022 to ~10.7M in FY2026), reducing financial flexibility if losses persist.
Income Statement
18Very NegativeBalance Sheet
46NeutralCash Flow
22Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.50M | 11.50M | 21.85M | 26.06M | 19.62M | 11.45M |
| Gross Profit | -107.00K | -936.00K | 8.44M | 14.31M | 9.60M | 4.56M |
| EBITDA | -34.94M | -35.23M | -31.35M | ― | -32.80M | -21.80M |
| Net Income | -35.78M | -35.78M | -29.94M | -29.54M | -26.96M | -19.79M |
Balance Sheet | ||||||
| Total Assets | 17.60M | 17.60M | 37.03M | 65.45M | 97.12M | 124.03M |
| Cash, Cash Equivalents and Short-Term Investments | 7.78M | 7.78M | 22.57M | 50.26M | 77.79M | 105.41M |
| Total Debt | 1.28M | 1.28M | 2.90M | 4.21M | 1.22M | 1.92M |
| Total Liabilities | 6.94M | 6.94M | 10.95M | 10.83M | 8.71M | 7.43M |
| Stockholders Equity | 10.66M | 10.66M | 26.09M | 54.62M | 88.41M | 116.60M |
Cash Flow | ||||||
| Free Cash Flow | -32.05M | -32.07M | -26.01M | -27.12M | -28.48M | -18.68M |
| Operating Cash Flow | -31.94M | -31.94M | -24.74M | -25.75M | -25.57M | -17.55M |
| Investing Cash Flow | 12.95M | 12.95M | 6.70M | 22.19M | 22.47M | -52.13M |
| Financing Cash Flow | 17.48M | 17.48M | -1.64M | -1.11M | -1.28M | 100.66M |
Pacific Edge Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:PEB, the sentiment is Neutral. The current price of 0.26 is below the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.25, and above the 200-day MA of 0.24, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 48.79 is Neutral, neither overbought nor oversold. The STOCH value of 32.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NZ:PEB.
Pacific Edge Limited Peers Comparison
Overall Rating
NZ:FPH80Outperform
NZ:EBO56Neutral
NZ:AFT54Neutral
NZ:PEB42Neutral
NZ:TRU37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | NZD 29.03B | 61.61 | 22.84% | 1.24% | 15.59% | 23.94% | |
| 56Neutral | NZD 4.54B | 16.71 | 7.99% | 5.69% | 16.36% | 5.52% | |
| 54Neutral | NZD 485.57M | 32.46 | 14.07% | 0.64% | 22.44% | 23.14% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | NZD 341.52M | -6.66 | -190.54% | ― | -47.36% | -3.79% | |
| 37Underperform | NZD 8.38M | -2.58 | -75.57% | ― | 42.20% | 23.68% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NZ:PEB | Pacific Edge Limited | 0.26 | 0.07 | 40.88% | |
| NZ:EBO | EBOS Group Limited | 21.65 | -5.75 | -20.98% | |
| NZ:FPH | Fisher & Paykel Healthcare Corporation Limited | 49.29 | 12.57 | 34.25% | |
| NZ:TRU | TruScreen Group Ltd. | 0.01 | -0.01 | -41.18% | |
| NZ:AFT | AFT Pharmaceuticals Ltd. | 4.59 | 0.93 | 25.38% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 05, 2026
